ATLASATLAS fair value
ATLAS has no fair value for this stock today.
Surrozen (SRZN)
Surrozen stock price today, ATLAS forecast and fair value
Healthcare · Biotechnology · NASDAQ
$29.48▲ +8.06%
Prices as of Oct 27, 2026 · USD
Chance of rising in 1 month
40%
that it ends higher than today in 21 sessions
0%coin flip 50%100%
This is just the summary. See everything on Surrozen in ATLAS
ATLAS's own quantitative analysis, all in one place.
- Simulation and expected rangeThousands of simulated scenarios: how far the price could rise or fall.
- Officers and shareholdersWho runs the company and which funds hold its shares.
- Customer and supplier mapWho it does business with, from its own filings.
- ATLAS builds your portfolioAnswer a short test and get portfolios that fit you.
- AlertsWe let you know when something changes in your stocks.
See everything included
- Valuation and financialsFair value step by step, quarterly accounts and upcoming events.
- NewsThe latest on the company, in one place.
- Crisis simulatorHow your portfolio would do in a crash like 2008.
- Practice risk-free$10,000 in virtual money to invest at real prices.
- Global screenerSearch US stocks and stocks from 47 countries with filters.
On Surrozen
- Simulation and expected rangeThousands of simulated scenarios: how far the price could rise or fall.
- Officers and shareholdersWho runs the company and which funds hold its shares.
- Customer and supplier mapWho it does business with, from its own filings.
- Valuation and financialsFair value step by step, quarterly accounts and upcoming events.
- NewsThe latest on the company, in one place.
And for you
- ATLAS builds your portfolioAnswer a short test and get portfolios that fit you.
- AlertsWe let you know when something changes in your stocks.
- Crisis simulatorHow your portfolio would do in a crash like 2008.
- Practice risk-free$10,000 in virtual money to invest at real prices.
- Global screenerSearch US stocks and stocks from 47 countries with filters.
Plans from €3.99 a month.
ATLAS's model gives Surrozen a 40% chance of finishing higher a month from now (21 trading sessions) than today: somewhat worse than a coin flip.
In half of the simulated outcomes the price ends between $20.47 and $35.05; in 9 out of 10, between $12.71 and $56.48. Estimated annual volatility is 173%.
Price, last 12 months (weekly close)
Key numbers
- Market cap
- $345M
- 52-week high
- $37.83
- 52-week low
- $11.39
- Revenue (12 months)
- $11.5M
- Revenue growth (YoY)
- -67.4%
- Gross margin
- 0.0%
- Return on equity
- 128.9%
- Free cash flow (12 months)
- $-21.8M
- Beta
- 0.56
What this means
ATLAS does not publish a fair value for SRZN right now, but it does show its odds of rising: somewhat worse than a coin flip.
Over the last 52 weeks SRZN has traded between $11.39 and $37.83. Today it is 22.1% below that high and 159% above its low.
Its beta is 0.56: it tends to move less than the market.
About the company
Surrozen, Inc. is a biotechnology company focused on developing antibody-based therapeutics that selectively modulate the Wnt pathway to support tissue repair and regeneration.
Want to see everything about Surrozen?
Get started →Plans from €3.99 a month.
Comparable companies
Other companies in the same line of business:
Frequently asked questions
What does Surrozen do?
Surrozen, Inc. is a biotechnology company focused on developing antibody-based therapeutics that selectively modulate the Wnt pathway to support tissue repair and regeneration.
What is the chance SRZN goes up next month?
40%: somewhat worse than a coin flip. In half of the simulated outcomes, SRZN ends the month between $20.47 and $35.05.
How big is Surrozen and what is its P/E ratio?
Surrozen's market capitalization is $345M. We do not show a P/E because it has no positive earnings to base one on.
How volatile is SRZN?
ATLAS estimates annual volatility at 173%. In a typical month, half of the outcomes end between $20.47 and $35.05.
Not investment advice. ATLAS estimates are produced by statistical models from public data; they can be wrong and past performance does not predict future results. Consider your own situation before investing. Disclaimer